ProCE Banner Activity

PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Emerging Mechanisms and Implications for Clinical Practice on the Horizon

Clinical Thought

This expert-led commentary summarizes the latest data and clinical pearls with PROTAC ER degraders and future application for ER+/HER2- MBC that has progressed after endocrine therapy.

Released: January 21, 2025

Expiration: January 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Pfizer Inc.

Pfizer Inc.

Disclosure

Primary Author

Erika Hamilton, MD

Chair, Breast Executive Committee
Director, Breast Cancer Research Program
Sarah Cannon Research Institute
SCRI Oncology Partners
Nashville, Tennessee

Erika Hamilton, MD: researcher (paid to institution): AbbVie, Acerta , Accutar, ADC Therapeutics, Akeso Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss BioPharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Cascadian, Clovis, Compugen, Context, Cullinan, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Dantari, Deciphera, Duality Biologics, eFFECTOR, Eisai, Ellipses Pharma, Elucida Oncology, EMD Serono, Fochon, FujiFilm, G1 Therapeutics, Gilead, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity, Inspirna, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind, Leap, Lilly, Loxo Oncology, Lycera, MabSpace Biosciences, MacroGenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema, OncoMed, Oncothyreon, Oric, Orinove, Orum, Pfizer, PharmaMar, Pieris, Pionyr Immunotherapeutics, Plexxikon, Prelude, Profound Bio, Radius Health, Regeneron, Relay, Repertoire Immune Medicine, Rgenix, Roche/Genentech, Seagen, Sermonix, Shattuck Labs, Silverback, Stemcentrx, Stemline, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque, Treadwell, Verastem, Zenith Epigenetics, Zymeworks; consultant/advisor (paid to institution): Accutar, Arvinas, AstraZeneca, BeiGene, Circle, Daiichi Sankyo, Entos, Gilead, Incyclix Bio, Iqvia, Janssen, Jazz, Jefferies, Johnson & Johnson, Lilly, Medical Pharma Services, Mersana, Novartis, Pfizer, Pyxis Oncology, Roche/Genentech, Samsung Bioepis, Shorla, Stemline, Tempus Labs, Theratechnologies, Zentalis.